NSE · BSE · Real-time
High-value corporate events — new orders, fund raises, capacity expansions, and earning calls — analysed by AI the moment they hit the exchange.
Glenmark Specialty S.A. has advanced its multi-country Phase 3 clinical trial for Trastuzumab rezetecan, a HER2-targeted antibody-drug conjugate. India marks the initial site for patient enrollment following DCGI approval, with further expansion planned for Australia and South Korea.
Real-time NSE & BSE event alerts, AI-summarized filings, and instant order-win signals — free for 15 days, no card required.
